Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
Tuesday, 21 August 2012
Implant Sciences says QS-B220 detection device moves to final phase of testing approval
Implant Sciences Corp. (PINK:IMSC) said Tuesday its explosives and narcotics trace detector completed readiness certification testing with the Transportation Security Laboratory.
The high-tech supplier of systems and sensors for homeland security markets said its Quantum Sniffer QS-B220 device is now undergoing final independent validation testing for air cargo screening for the Transportation Safety Administration.
The benchtop explosives and narcotics detector is suited for a number of security settings, including high-traffic airports and borders.
"This is a major milestone for the company," chief executive Glenn D. Bolduc said in a release Tuesday.
"Entering into this final phase of approval gives us great confidence that our desktop B220 explosives trace detection system will be well positioned for adoption in the U.S. and global markets."
"While the next few weeks will be a quiet period during the final stage of testing, we remain confident in our system's performance and are hopeful that we will have good news to report to our shareholders by the end of our fiscal first quarter," he added.
Implant Sciences also makes the Quantum Sniffer QS-H150, which is a trace detector that utilizes ion mobility spectrometry to find a number of military, commercial or homemade explosives.
The QS-H150 uses no radioactive materials and has a low-maintenance design.
Earlier this month, the company announced new sales of its explosives trace detection system in Nigeria for aviation security.
The latest shipment went to ASL Airlines Services in Lagos, and the sale was made through A.C. Belgrave, an in-country distributor for Implant Sciences' products.